A Long-Term Safety Study of Tenapanor for the Treatment of IBS-C
Status:
Completed
Trial end date:
2017-10-01
Target enrollment:
Participant gender:
Summary
This phase 3, open label study will evaluate the safety of tenapanor 50 mg BID in subjects
with constipation-predominant irritable bowel syndrome (IBS-C) defined by the ROME III
criteria. Subjects who have completed either TEN-01-301 (16 weeks) or TEN-01-302 (26 weeks)
studies may be enrolled. Subjects will take tenapanor for approximately 52-55 weeks total
based on previous protocol and this study.